TYK2 Inhibitors

Next-Gen TYK2 Inhibition: Redefining Oral, Systemic Treatment for Psoriasis

<p>In this session, Jason Hawkes, MD, explores the next wave of TYK2 inhibitors and how emerging molecules differ from first-generation agents. Dr Hawkes discusses the immunologic rationale for targeting the TYK2 pathway in plaque psoriasis and why these therapies represent an exciting step forward in oral treatment options.</p><p>He also reviews how to recognize the “systemic-ready” patient, including those who remain undertreated due to limited body surface involvement, and how understanding the immunology behind TYK2 inhibition can help clinicians translate these advances into more effective, individualized care.</p>

TYK2 Inhibitors Condition Center

Featured in TYK2 Inhibitors

Next-Gen TYK2 Inhibition: Redefining Oral, Systemic Treatment for Psoriasis